Month: October 2020

Moderna Announces Initiation of Rolling Submission to Health Canada for mRNA Vaccine Against COVID-19 (mRNA-1273)

10/20/2020

Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the initiation of a rolling submission to Health Canada for mRNA-1273, the Company’s vaccine candidate against COVID-19. This initiation follows positive results…

Read More

Journal of Affective Disorders Publishes Clinical Data Suggesting NeuroStar® Advanced Therapy as a First-line Treatment for Major Depressive Disorder

10/19/2020

Excerpt from the Press Release: MALVERN, Pa., Oct. 13, 2020 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, announced today that clinical data from its NeuroStar Outcomes Registry, which suggests…

Read More

Sorrento Announces the Discovery of Salicyn-30 Small Molecule That Strongly Inhibits SARS-CoV-2 Infection in Preclinical Studies and Highlights its Place in a Potential Multi-Modal Therapy Strategy in Combination With Neutralizing Antibodies Against COVID

10/16/2020

Excerpt from the Press Release: SAN DIEGO, Oct. 07, 2020 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today that it has discovered a small molecule termed Salicyn-30 that demonstrated a potent 3-4 log reduction of SARS-CoV-2 virus infection in an in vitro virus infection experiment. Since the beginning of the COVID-19 pandemic, Sorrento has…

Read More

Ocular Therapeutix™ Announces Topline Phase 1 Clinical Trial Results of OTX-CSI

10/15/2020

Excerpt from the Press Release: BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced topline Phase 1 clinical trial results of OTX-CSI (cyclosporine intracanalicular insert) for the treatment of dry eye disease (DED). “The results…

Read More

Nobel Prize in Chemistry

10/14/2020

Excerpt from the Press Release: ZUG, Switzerland and CAMBRIDGE, Mass., Oct. 07, 2020 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), today announced Professor Emmanuelle Charpentier, CRISPR Therapeutics’ co-founder, has been awarded the 2020 Nobel Prize in Chemistry for her groundbreaking work on the CRISPR/Cas9 system. Professor Charpentier co-founded CRISPR Therapeutics together with Rodger Novak and Shaun…

Read More

Aprea Therapeutics Receives OK from FDA to Initiate Phase 1 Clinical Studies for Next-Generation Mutant p53 Reactivator, APR-548

10/13/2020

Excerpt from the Press Release: BOSTON, Oct. 07, 2020 (GLOBE NEWSWIRE) — Aprea Therapeutics Inc., (NASDAQ: APRE), a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s Investigational New Drug (IND) application…

Read More

Revelation Biosciences Inc. Receives TGA Acknowledgment to Start a Phase 1 Clinical Study of REVTx‑99 an Experimental Treatment for COVID‑19

10/12/2020

Excerpt from the Press Release: MENLO PARK, Calif.–(BUSINESS WIRE)–Revelation Biosciences Inc. (Revelation), a clinical stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease, announced today that it received acknowledgement by the Therapeutic Goods Administration (TGA) in Australia to conduct a Phase 1 clinical study of REVTx‑99…

Read More

Revelation Biosciences Inc. Receives Approval to Start a Phase 1 Clinical Study of REVTx-99 an Experimental Treatment for COVID-19

10/09/2020

Excerpt from the Press Release: MENLO PARK, Calif.–(BUSINESS WIRE)–Revelation Biosciences Inc. (Revelation), a clinical stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease, announced today that it has been granted approval by the Bellberry Human Research Ethics Committee (HREC) in Australia to conduct a Phase 1…

Read More

Hologic Announces Multi-Year, Multi-Pronged Commitment to Tackling Breast Cancer Screening Disparities for Black Women in Partnership with the Black Women’s Health Imperative and RAD-AID

10/08/2020

Excerpt from the Press Release: MARLBOROUGH, Mass.–(BUSINESS WIRE)–Hologic, Inc. (Nasdaq: HOLX), an innovative medical technology company primarily focused on improving women’s health, today announced a multi-year commitment to decreasing breast cancer screening disparities for Black women. The program is in partnership with the Black Women’s Health Imperative (BWHI), the only nonprofit organization created by Black…

Read More

UC San Diego Health Joins International Clinical Trial to Test Coronavirus Vaccine

10/07/2020

Excerpt from the Article: UC San Diego Health will be a test site for a third, major Phase III clinical trial to assess a vaccine candidate for SARS-CoV-2, the novel coronavirus that causes COVID-19. Sponsored by Janssen Pharmaceuticals Companies of Johnson & Johnson, the trial will recruit up to 60,000 participants at sites in the…

Read More